IRIS
BOCCHIA, MONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.324
EU - Europa 14.866
AS - Asia 2.580
AF - Africa 61
SA - Sud America 60
OC - Oceania 27
Continente sconosciuto - Info sul continente non disponibili 12
Totale 34.930
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.271
GB - Regno Unito 4.156
IE - Irlanda 2.663
IT - Italia 2.147
CN - Cina 1.648
UA - Ucraina 1.374
SE - Svezia 1.185
RU - Federazione Russa 1.176
FR - Francia 768
DE - Germania 621
SG - Singapore 547
FI - Finlandia 434
VN - Vietnam 124
TR - Turchia 67
NL - Olanda 66
BE - Belgio 62
IN - India 46
CA - Canada 42
CZ - Repubblica Ceca 40
CI - Costa d'Avorio 30
PL - Polonia 26
BR - Brasile 25
IR - Iran 25
JP - Giappone 25
ES - Italia 22
HK - Hong Kong 21
AU - Australia 20
EE - Estonia 19
EG - Egitto 17
LT - Lituania 16
AR - Argentina 13
CL - Cile 11
CH - Svizzera 10
EU - Europa 9
GR - Grecia 9
MA - Marocco 9
RO - Romania 9
AT - Austria 7
DK - Danimarca 7
NZ - Nuova Zelanda 7
PH - Filippine 7
LU - Lussemburgo 6
MX - Messico 6
MY - Malesia 6
PT - Portogallo 6
RS - Serbia 6
SA - Arabia Saudita 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
EC - Ecuador 5
HR - Croazia 5
IL - Israele 5
LA - Repubblica Popolare Democratica del Laos 5
LV - Lettonia 5
SK - Slovacchia (Repubblica Slovacca) 5
BO - Bolivia 4
ID - Indonesia 4
TH - Thailandia 4
UZ - Uzbekistan 4
BG - Bulgaria 3
DO - Repubblica Dominicana 3
IM - Isola di Man 3
JO - Giordania 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LK - Sri Lanka 3
NG - Nigeria 3
PK - Pakistan 3
AM - Armenia 2
BD - Bangladesh 2
CW - ???statistics.table.value.countryCode.CW??? 2
DZ - Algeria 2
KR - Corea 2
PE - Perù 2
SM - San Marino 2
A1 - Anonimo 1
AL - Albania 1
BY - Bielorussia 1
HU - Ungheria 1
IQ - Iraq 1
IS - Islanda 1
JM - Giamaica 1
KH - Cambogia 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
NO - Norvegia 1
PA - Panama 1
SI - Slovenia 1
TM - Turkmenistan 1
TW - Taiwan 1
Totale 34.930
Salva come PNG Salva come JPEG
Città #
Southend 3.821
Dublin 2.648
Fairfield 2.487
Ashburn 1.516
Chandler 1.353
Houston 1.245
Woodbridge 1.239
Jacksonville 1.112
Santa Clara 1.094
Wilmington 1.001
Seattle 955
Cambridge 789
Ann Arbor 648
Siena 536
Princeton 523
Singapore 408
Nanjing 400
Beijing 323
Boardman 203
Helsinki 200
San Mateo 179
Florence 159
San Diego 133
Dearborn 125
Dong Ket 122
Milan 122
Nanchang 117
New York 115
Moscow 105
Rome 88
Shanghai 87
Hebei 82
London 76
Shenyang 75
Tianjin 69
Brussels 56
Kunming 56
Menlo Park 53
Jiaxing 52
Izmir 50
Jinan 46
Munich 44
Changsha 40
Falls Church 40
Norwalk 40
Los Angeles 35
Turin 35
Brno 33
Düsseldorf 31
Washington 31
Abidjan 30
Hangzhou 27
Guangzhou 26
Lappeenranta 26
Ningbo 26
San Francisco 26
Toronto 23
Zhengzhou 22
Fremont 21
Hefei 20
Kilburn 20
Lanzhou 19
Tallinn 19
Amsterdam 17
Bologna 17
Frankfurt am Main 17
Taizhou 17
Dallas 16
Changchun 14
Edinburgh 14
Haikou 13
Hong Kong 13
Livorno 13
North Bergen 13
Padova 13
Redwood City 13
Chiswick 12
Málaga 12
Venezia 12
Atlanta 11
Hounslow 11
Leawood 11
Naples 11
Palermo 11
Bari 10
Cairo 10
New Bedfont 10
Poggibonsi 10
Salerno 10
Stockholm 10
Verona 10
Colle Di Val D'elsa 9
Groningen 9
Lucca 9
Monza 9
Newark 9
Phoenix 9
Pisa 9
Sutri 9
The Dalles 9
Totale 25.534
Salva come PNG Salva come JPEG
Nome #
VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases 553
null 398
Mycosis Fungoides: a therapeutical review 328
MACOP-B versus F-MACHOP regimen in the treatment of high grade Non-Hodgkin’s Lymphomas 301
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 221
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 220
Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: Are some patients more sensitive to IV bortezomib? 210
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 210
Low-level TP53 mutational load antecedes clonal expansion in chronic lymphocytic leukaemia 207
Decreased plasma endogenous soluble RAGE, and enhanced adipokine secretion, oxidative stress and platelet/coagulative activation identify non-alcoholic fatty liver disease among patients with familial combined hyperlipidemia and/or metabolic syndrome 204
Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status? 203
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 202
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients 201
Second generation proteasome inhibitors in multiple myeloma 199
Human cytotoxic T lymphocytes form dysfunctional immune synapses with B cells characterized by non-polarized lytic granule release 181
New perspectives for patients with primary CNS lymphoma 179
Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab 176
Central nervous system multiple myeloma 172
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. 171
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura 169
Unravelling the response of chronic lymphocytic leukemia to a novel class of anticancer agents, the pyrrolonaphthoxazepines (PNOXs) 167
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia 166
Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis 165
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 165
Lenalidomide and temozolomide combination in a very elderly patient with CNS relapse of diffuse large B-cell lymphoma 165
Variant Philadelphia translocations: Molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA working party on CML analysis 164
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party 161
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 161
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib 161
Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma 160
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 159
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia 159
Prognostic significance of lymphocyte/monocyte count and neutrophil/lymphocyte count in peripheral T cell lymphoma 159
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses 158
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia 158
Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma 157
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 157
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia 155
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 154
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients 154
Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment 154
Emerging drugs in chronic myelogenous leukaemia 153
Atherothrombotic risk assessment during tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients: new insight? 153
Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma 153
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice 151
Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy 151
Evolving treatments in multiple myeloma patients with renal failure 150
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 150
Therapeutic use of Brentuximab Vedotin In Cd30+ hematologic malignancies 148
Long term remission in a case of Plasmablastic lymphoma treated with COMP (Cyclophosphamide, Liposomal Doxorubicin, Vincristine, Prednisone) and Bortezomib 148
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 148
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 147
Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML working party analysis 146
Primary Nasopharyngeal Hodgkin Lymphoma 146
Peptide vaccines for hematological malignancies: a missed promise? 145
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy 145
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 144
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party 144
Prognostic role of m2 Tumour-Associated macrophages in lymphoproliferative disorders 144
Treatment of smoldering multiple myeloma 143
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients 143
Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review 143
Chronic myeloid leukaemia with extreme thrombocytosis at presentation: Incidence, clinical findings and outcome 141
Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. 141
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP 141
Radiotherapy with rituximab as first-line treatment for early-stage follicular lymphoma 140
Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia 140
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may explain increased atherothrombotic risk during TKI treatment in chronic myeloid leukemia patients 138
Anaplastic large cell lymphoma (CD30+/Ki-1+): results of a prospective clinico-pathological study of 69 cases 137
A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): A case report 137
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia 137
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia 137
Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET 137
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, Philadelphia-positive chronic myeloid leukemia: The GIMEMA working party on CML 137
Hyperlipidemia in a myeloma patient after bortezomib treatment 136
Unusual localizations of plasmacytoma 136
Identification of a Novel P190-Derived Breakpoint Peptide Suitable for Peptide Vaccine Therapeutic Approach in Ph+ Acute Lymphoblastic Leukemia Patients. 135
Differences among young adults, adults and elderly chronic myeloid leukemia patients 135
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 135
Primary CNS lymphoma: latest updates and a 10-year monocenter experience 135
Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes. 134
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: A phase 2 trial of the GIMEMA CML Working Party 134
A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2 134
Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas 134
Treatment decisions and outcome in very elderly patients with diffuse large B-Cell lymphoma 134
The response to imatinib and interferon- is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 134
Extramedullary myeloma relapses 133
Alpha-2b recombinant interferon (Intron) in Hodgkins' lymphoma: Therapeutic perspective 132
Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib 132
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML Working Party experience after a 7-year follow-up 131
null 130
Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas 130
A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia 130
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline 129
FLT3 inhibitors in the management of acute myeloid leukemia 128
Central Nervous System Multiple Myeloma 127
Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma 127
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 127
Fludarabine: An active agent in the treatment of previously treated and untreated low grade non-Hodgkin's lymphoma 126
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 125
Totale 16.245
Salva come PNG Salva come JPEG
Categoria #
all - tutte 124.296
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 124.296
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.798 0 0 0 0 0 554 587 905 593 586 165 408
2020/20215.411 242 628 274 570 307 572 300 785 483 410 397 443
2021/20223.671 264 441 256 332 154 154 137 140 202 404 419 768
2022/20235.251 333 348 634 714 510 1.032 129 476 534 69 343 129
2023/20244.645 182 119 368 336 175 1.035 1.407 397 62 127 87 350
2024/20253.951 334 507 935 547 1.083 545 0 0 0 0 0 0
Totale 35.683